

# Christopher Sjwall

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7612358/christopher-sjwall-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141  
papers

2,691  
citations

31  
h-index

44  
g-index

179  
ext. papers

3,574  
ext. citations

4.7  
avg, IF

5.22  
L-index

#	Paper	IF	Citations
141	The Diagnostic Performance of an Extended Ultrasound Protocol in Patients With Clinically Suspected Giant Cell Arteritis.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 807996	4.9	0
140	Comment on Systemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challenge. <i>Scandinavian Journal of Rheumatology</i> , <b>2021</b> , 1-2	1.9	1
139	Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2021</b> , 1	3.9	1
138	Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 722758	4.9	2
137	De novo lupus nephritis during treatment with belimumab. <i>Rheumatology</i> , <b>2021</b> , 60, 4348-4354	3.9	8
136	Interaction between the rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1183-1189	2.4	1
135	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	4
134	Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 661101	4.9	0
133	POS0601 DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIRST USERS OF EACH MOLECULE. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 535.2-535	2.4	1
132	Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2021</b> , 30, 1244-1253	2.6	0
131	Pentraxin-3 detected in human saliva shows limited correlation with biomarkers associated with systemic inflammation. <i>Apmis</i> , <b>2021</b> , 129, 304-313	3.4	2
130	POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 864-865	2.4	1
129	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 688753	8.4	3
128	Variants in BANK1 are associated with lupus nephritis of European ancestry. <i>Genes and Immunity</i> , <b>2021</b> , 22, 194-202	4.4	2
127	Contributions of de novo variants to systemic lupus erythematosus. <i>European Journal of Human Genetics</i> , <b>2021</b> , 29, 184-193	5.3	2
126	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 109-117	2.4	10
125	Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes. <i>Clinical and Experimental Immunology</i> , <b>2021</b> , 203, 22-31	6.2	2

124	Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome. <i>Scandinavian Journal of Rheumatology</i> , <b>2021</b> , 50, 1-10	1.9	2
123	Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 645298	4.1	0
122	Longitudinal Analysis of Anti-cardiolipin and Anti- $\beta$ -glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 646846	4.9	3
121	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	37
120	SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 724047	8.4	5
119	Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 722118	8.4	1
118	Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
117	A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity. <i>Scandinavian Journal of Rheumatology</i> , <b>2021</b> , 1-3	1.9	0
116	Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 756941	8.4	1
115	Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 1360-1368	2.2	1
114	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	1
113	The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus.. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
112	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	11
111	Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. <i>Lupus</i> , <b>2020</b> , 29, 625-630	2.6	2
110	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1387-1393	5.3	6
109	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 316	4.9	21
108	AB0321 EFFECT ON RETENTION RATES OF A NOVEL AUTOINJECTOR E-DEVICE IMPLEMENTED IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL; A MULTI-CENTRE STUDY. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1459.1-1459	2.4	
107	AB0400 PATIENT-REPORTED OUTCOME MEASURES IN SWEDISH PATIENTS WITH RECENT-ONSET SLE VERSUS RA IN THE FIRST 60 MONTHS AFTER DIAGNOSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1499.2-1500	2.4	

106	NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 254-261	2.4	18
105	Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives. <i>Clinical and Experimental Immunology</i> , <b>2020</b> , 199, 143-149	6.2	2
104	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
103	Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. <i>Clinical and Experimental Immunology</i> , <b>2020</b> , 199, 245-254	6.2	14
102	High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 363-369	2.4	39
101	High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 581336	4.9	6
100	P137 De novo lupus nephritis during belimumab treatment <b>2020</b> ,		1
99	Synthesis of an Array of Triple-Helical Peptides from Type II Collagen for Multiplex Analysis of Autoantibodies in Rheumatoid Arthritis. <i>ACS Chemical Biology</i> , <b>2020</b> , 15, 2605-2615	4.9	1
98	Adverse Pregnancy Outcomes after Multi-Professional Follow-Up of Women with Systemic Lupus Erythematosus: An Observational Study from a Single Centre in Sweden. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
97	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 578848	8.4	2
96	Correspondence on Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	1
95	Elevated free secretory component in early rheumatoid arthritis and prior to arthritis development in patients at increased risk. <i>Rheumatology</i> , <b>2020</b> , 59, 979-987	3.9	1
94	Toll-like receptors revisited; a possible role for TLR1 in lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	2
93	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 622326	8.4	9
92	Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 607166	8.4	3
91	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
90	Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. <i>Human Genetics</i> , <b>2019</b> , 138, 141-150	6.3	32
89	The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable. <i>Lupus</i> , <b>2019</b> , 28, 778-782	2.6	33

88	Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 82	5.6	24
87	Shared and Unique Patterns of DNA Methylation in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1686	8.4	20
86	Low Production of Reactive Oxygen Species Drives Systemic Lupus Erythematosus. <i>Trends in Molecular Medicine</i> , <b>2019</b> , 25, 826-835	11.5	12
85	The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts. <i>Lupus</i> , <b>2019</b> , 28, 1261-1272	2.6	11
84	Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1363-1370	3.7	32
83	Neutrophil Extracellular Traps (NETs) in the Cerebrospinal Fluid Samples from Children and Adults with Central Nervous System Infections. <i>Cells</i> , <b>2019</b> , 9,	7.9	12
82	Sex differences in clinical presentation of systemic lupus erythematosus. <i>Biology of Sex Differences</i> , <b>2019</b> , 10, 60	9.3	15
81	Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 259	5.7	7
80	A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. <i>European Journal of Human Genetics</i> , <b>2019</b> , 27, 432-441	5.3	10
79	Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 320-327	2.4	31
78	Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1063-1069	2.4	21
77	Uptake of rheumatology biosimilars in the absence of forced switching. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 499-504	5.4	8
76	DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 736-743	2.4	76
75	Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). <i>Rheumatology</i> , <b>2018</b> , 57, 1400-1407	3.9	28
74	Response to: Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself? by Bruzzese and Zullo. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e72	2.4	
73	Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus. <i>Journal of Immunology Research</i> , <b>2018</b> , 2018, 1294680	4.5	6
72	Active NET formation in Libman-Sacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. <i>Autoimmunity</i> , <b>2018</b> , 51, 310-318	3	6
71	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , <b>2018</b> , 194, 27-38	6.2	9

70	The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. <i>Journal of Immunological Methods</i> , <b>2018</b> , 459, 11-19	2.5	40
69	Smoking reduces the efficacy of belimumab in mucocutaneous lupus. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 911-920	5.4	11
68	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 343-351	13.6	52
67	Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. <i>Lupus</i> , <b>2017</b> , 26, 1333-1338	2.6	14
66	Interferon- $\alpha$ coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 189, 83-91	6.2	11
65	P1_144 Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden. <i>Rheumatology</i> , <b>2017</b> , 56, iii88-iii88	3.9	
64	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1544-1549	2.4	61
63	Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 189, 372-382	6.2	17
62	A single nucleotide polymorphism in the gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1607-1613	2.4	65
61	Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000225	4.6	14
60	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , <b>2017</b> , 8, 16021	17.4	171
59	Novel risk genes for systemic lupus erythematosus predicted by random forest classification. <i>Scientific Reports</i> , <b>2017</b> , 7, 6236	4.9	31
58	Cervical neoplasia in systemic lupus erythematosus: a nationwide study. <i>Rheumatology</i> , <b>2017</b> , 56, 613-619	3.9	14
57	Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. <i>Cell Reports</i> , <b>2016</b> , 16, 2928-2939	10.6	28
56	OP0189 Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 128.2-128	2.4	
55	International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies. <i>Lupus</i> , <b>2016</b> , 25, 864-72	2.6	20
54	Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 684-90	5.3	12
53	Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells. <i>Journal of Virology</i> , <b>2016</b> , 90, 4939-4950	6.6	11



52	Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165373	3.7	33
51	Case definitions in Swedish register data to identify systemic lupus erythematosus. <i>BMJ Open</i> , <b>2016</b> , 6, e007769	3	24
50	THU0345 Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and $\beta$ -Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 312.1-312	2.4	
49	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 289	5.7	32
48	Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases. <i>BMC Musculoskeletal Disorders</i> , <b>2016</b> , 17, 246	2.8	8
47	What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 988-94	4.7	42
46	Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 3	5.7	67
45	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. <i>Translational Research</i> , <b>2015</b> , 165, 658-66	11	22
44	Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement. <i>Scandinavian Journal of Rheumatology</i> , <b>2015</b> , 44, 337-9 <sup>1.9</sup>		2
43	Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. <i>BMC Musculoskeletal Disorders</i> , <b>2015</b> , 16, 188	2.8	30
42	Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 569-81	2.6	48
41	Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 338	5.7	26
40	Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?. <i>Clinica Chimica Acta</i> , <b>2015</b> , 444, 234-41	6.2	19
39	Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 817-25	4.1	40
38	Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30 Suppl 1, i23-30	4.3	8
37	Individual variations in treatment decisions by Swedish rheumatologists regarding biological drugs for rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2015</b> , 44, 265-70	1.9	1
36	Complement opsonization of HIV-1 results in decreased antiviral and inflammatory responses in immature dendritic cells via CR3. <i>Journal of Immunology</i> , <b>2014</b> , 193, 4590-601	5.3	30
35	Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. <i>Scandinavian Journal of Rheumatology</i> , <b>2014</b> , 43, 428-30	1.9	21

34	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1259-67	13.4	18
33	Association of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon- $\beta$ and a C-reactive protein gene variant. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 1568-73	9.5	23
32	A3.7 No evidence of cathelicidin being involved in the pathogenesis of lupus and arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A44.2-A45	2.4	
31	THU0042 Autoantibodies against High Mobility Group Box Protein-1 in Systemic Lupus Erythematosus: Association with Disease Activity and Other Antinuclear Antibodies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 191.1-191	2.4	
30	FRI0172 Utility of Swedish Register Data in Classifying Systemic Lupus. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 444.2-444	2.4	
29	No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis. <i>PLoS ONE</i> , <b>2014</b> , 9, e115474	3.7	26
28	Systemic lupus erythematosus prevalence in Sweden in 2010: what do national registers say?. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1710-7	4.7	24
27	Association of genes in the NF- $\kappa$ B pathway with antibody-positive primary Sjögren's syndrome. <i>Scandinavian Journal of Immunology</i> , <b>2013</b> , 78, 447-54	3.4	37
26	Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. <i>Translational Research</i> , <b>2013</b> , 162, 287-96	11	39
25	C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. <i>Autoimmunity</i> , <b>2013</b> , 46, 205-14	3	26
24	Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. <i>BMJ Open</i> , <b>2013</b> , 3, e003608	3	33
23	Contribution of IKBKE and IFIH1 gene variants to SLE susceptibility. <i>Genes and Immunity</i> , <b>2013</b> , 14, 217-22.4	2.4	22
22	Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. <i>European Journal of Human Genetics</i> , <b>2013</b> , 21, 994-9	5.3	62
21	Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. <i>PLoS ONE</i> , <b>2013</b> , 8, e84450	3.7	62
20	High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. <i>Human Immunology</i> , <b>2012</b> , 73, 382-8	2.3	18
19	Common genetic variations in the NALP3 inflammasome are associated with delayed apoptosis of human neutrophils. <i>PLoS ONE</i> , <b>2012</b> , 7, e31326	3.7	29
18	Association between genetic variants in the tumour necrosis factor/lymphotoxin $\beta$ locus and primary Sjögren's syndrome in Scandinavian samples. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 981-8	2.4	41
17	Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. <i>Scandinavian Journal of Immunology</i> , <b>2011</b> , 74, 463-70	3.4	9



16	Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. <i>Genes and Immunity</i> , <b>2011</b> , 12, 100-9	4.4	97
15	Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (the Swedish TIRA project). <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 215-20	4.1	15
14	Dr. Skogh, et al, reply. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1834-1834	4.1	
13	Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 3755-60		63
12	Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. <i>Clinica Chimica Acta</i> , <b>2009</b> , 400, 128-31	6.2	16
11	Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R188	5.7	31
10	C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. <i>Immunology and Cell Biology</i> , <b>2008</b> , 86, 466-74	5	15
9	Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1994-2000	4.1	35
8	Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies. <i>Clinical and Experimental Immunology</i> , <b>2007</b> , 147, 513-20	6.2	30
7	Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. <i>Biochemical and Biophysical Research Communications</i> , <b>2007</b> , 352, 251-8	3.4	30
6	Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. <i>Clinica Chimica Acta</i> , <b>2007</b> , 378, 13-23	6.2	36
5	Anti-CRP autoantibody levels correlate with disease activity in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2005</b> , 35, 65; author reply 66	5.3	6
4	CRP and Anti-CRP Autoantibodies in Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , <b>2005</b> , 1, 81-89	1.6	6
3	Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. <i>Arthritis Research</i> , <b>2004</b> , 6, R87-94		71
2	Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2004</b> , 22, 315-23	15.5	32
1	Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren's syndrome, rheumatoid arthritis or inflammatory bowel disease. <i>Journal of Autoimmunity</i> , <b>2002</b> , 19, 155-60	15.5	50